Fetal Alcohol Syndrome and Essential Fatty Acids

Essential fatty acids (EFAs) are structural components of the brain and influence nerve conduction and transmitter release and action [ 1]. Prostaglandins (PGs) derived from EFAs and polyunsaturated fatty acids (PUFAs) modify nerve conduction and transmitter function. Ethanol (1) reduces blood linoleic acid (LA) levels; (2) blocks conversion of LA and gamma-linolenic acid (GLA) to arachidonic acid (AA), as well as alpha-linolenic acid (ALA) to eicosapentaenoic and docosahexaenoic acids (EPA and DHA, respectively), by inhibiting delta-6 and delta-5 desaturases; and (3) enhances the conversion of dihomo-gamma-linolenic acid (DGLA) to PGE1 [ 1]. 
 
Ethanol-enhanced interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) production suggest that immunological mechanisms play a role in ethanol-induced diseases. Cerebral cortex from chronic ethanol-fed rats showed up-regulation of inducible nitric oxide (iNOS), cyclo-oxygenase-2 (COX-2), IL-1-beta, and activation of transcription factors nuclear factor-kappa B (NF-kappa B) and AP-1—effects that increased both caspase-3 and apoptosis [ 2]. 
 
Brains of ethanol-treated mice show raised phospholipase-A2 and phospholipase-C activity [ 3] that can cause the release of AA, EPA, and DHA from membrane phospholipids. AA, EPA, and DHA form precursors to eicosanoids—lipoxins (LXs), resolvins, and neuroprotectin D1 (NPD1) [ 4]. LXs, resolvins, and NPD1 suppress IL-6 and TNF-alpha production. PGs, LXs, resolvins, and NPD1 precursor supplies are limited; therefore, when ethanol consumption is substantial, tissue concentrations of PUFAs decline, leading to a fall in the synthesis of various PGs, LXs, resolvins, and NPD1. 
 
DHA and other PUFAs released from the membrane in response to neurotransmitters [ 5] activate retinoid X receptor (RXR) as PUFAs form ligands for the RXR [ 6]. DHA deficiency results in impaired spatial learning and other abnormalities [ 7]. RXR heterodimerization partners peroxisome proliferator-activated receptors (PPARs), liver X receptors, and farnesoid X receptors that are essential for regulating energy and nutritional homeostasis. PUFAs, being ligands for RXR and PPARs, modulate these and other regulatory events by binding to these nuclear receptor heterodimers. 
 
AA, DHA, EPA, LXs, resolvins, and NPD1 have neuroprotective actions [ 4]; inhibit IL-6 and TNF-alpha production that is neurotoxic; and increase synthesis of endothelial nitric oxide (eNO), a neurotransmitter. When neurons are depleted of their PUFA content, as happens after high alcohol intake, formation of LXs, resolvins, and NPD1 will be suboptimal and, hence, neuronal death induced by TNF-alpha cannot be antagonized. This results in fetal alcohol syndrome (FAS). 
 
Nicotinamide is necessary for delta-6 desaturase and enhances the formation of various PUFAs and their products [ 8], suggesting that the neuroprotective action of nicotinamide against ethanol-induced FAS, as described by Alessandro Ieraci and Daniel Herrera [ 9], could be attributed to its action on these lipid pathways.


Fetal Alcohol Syndrome and Essential Fatty Acids Undurti N. Das
Essential fatty acids (EFAs) are structural components of the brain and infl uence nerve conduction and transmitter release and action [1]. Prostaglandins (PGs) derived from EFAs and polyunsaturated fatty acids (PUFAs) modify nerve conduction and transmitter function. Ethanol (1) reduces blood linoleic acid (LA) levels; (2) blocks conversion of LA and gammalinolenic acid (GLA) to arachidonic acid (AA), as well as alphalinolenic acid (ALA) to eicosapentaenoic and docosahexaenoic acids (EPA and DHA, respectively), by inhibiting delta-6 and delta-5 desaturases; and (3) enhances the conversion of dihomo-gamma-linolenic acid (DGLA) to PGE1 [1].
DHA and other PUFAs released from the membrane in response to neurotransmitters [5] activate retinoid X receptor (RXR) as PUFAs form ligands for the RXR [6]. DHA defi ciency results in impaired spatial learning and other abnormalities [7]. RXR heterodimerization partners peroxisome proliferator-activated receptors (PPARs), liver X receptors, and farnesoid X receptors that are essential for regulating energy and nutritional homeostasis. PUFAs, being ligands for RXR and PPARs, modulate these and other regulatory events by binding to these nuclear receptor heterodimers.
AA, DHA, EPA, LXs, resolvins, and NPD1 have neuroprotective actions [4]; inhibit IL-6 and TNF-alpha production that is neurotoxic; and increase synthesis of endothelial nitric oxide (eNO), a neurotransmitter. When neurons are depleted of their PUFA content, as happens after high alcohol intake, formation of LXs, resolvins, and NPD1 will be suboptimal and, hence, neuronal death induced by TNF-alpha cannot be antagonized. This results in fetal alcohol syndrome (FAS).
Nicotinamide is necessary for delta-6 desaturase and enhances the formation of various PUFAs and their products [8], suggesting that the neuroprotective action of nicotinamide against ethanol-induced FAS, as described by Alessandro Ieraci and Daniel Herrera [9], could be attributed to its action on these lipid pathways. We are grateful to Undurti Das for his suggestions regarding the possible mechanisms of action of nicotinamide in response to our research article [1,2]. He points to the metabolism of essential fatty acids and the infl ammatory responses observed after ethanol exposure. We, in fact, consider these important steps in the protection afforded by nicotinamide against ethanol-induced apoptosis, but, additionally, other possible mechanisms may be involved. The effects of nicotinamide appear to be very intricate and in need of more studies. For example, the effects of ethanol on delta-6 desaturase in the brain have not been studied in detail. The delta-6-desaturase increase was correlated with, and augmented, vitamin E levels in the brain [3]; however, in our preliminary studies, vitamin E did not ameliorate ethanolinduced apoptosis. All of the mechanisms described below do not exclude the importance of those described by Das. It has been shown that Bax mediates ethanol-induced apoptotic neuronal death in the developing brain [4]. Following an apoptotic stimulus, Bax translocates from the cytoplasm to the mitochondrial membrane, where it increases membrane permeability and promotes the release of cytochrome-c. This increase, in turn, induces activation of caspase-3, leading to cell death. Several mechanisms have been described to promote the translocation of Bax. Activation of the c-Jun N-terminal protein kinase (JNK) plays a critical role in Bax translocation [5]. Acute ethanol administration increases the activation of JNK in the postnatal cerebral cortex and striatum [6]. It has been shown that nicotinamide prevents the activation of JNK and the N-methyl-N-nitrosourea-induced apoptotic cell death in rat photoreceptor cells [7].
Inhibition of the phosphatidylinositol-3-kinase (PI3-K)/ Akt pathway is another cell death mechanism associated with the translocation of Bax [8]. Administration of ethanol decreases the activation of Akt in the developing postnatal rat brain [6]. Nicotinamide is able to increase the activation of Akt in primary hippocampal neuronal cell cultures, and this is necessary to protect against oxygen-glucose-deprivation (OGD)-induced apoptosis [9].
Several studies have pointed out that ethanol exposure increases the generation of reactive oxygen species in the developing brain [10]. Nicotinamide has been shown to act directly at the mitochondrial level by preventing the enhancement in mitochondrial permeability transition (MPT) pore opening and the release of cytochrome-c following exposure to OGD [9].
Cellular energy metabolism is another signifi cant factor that controls MPT pore formation, as the maintenance of mitochondrial membrane potential is an ATP-facilitated process. During oxidative stress, depletion of NAD, necessary for the production of ATP, is a critical step in precipitating cell death due to compromised energy supply. Nicotinamide administration increases the amount of NAD in the brain, and prevents its depletion and the consequent decrease of ATP [11].
We have demonstrated that nicotinamide prevents the ethanol-induced release of cytochrome-c and the following caspase-3 activation in brain development [2].
In conclusion, nicotinamide can prevent neuronal cell death by acting at different and probably complementary molecular levels.

Unique Author Identifi cation Number in Scientifi c Databases: A Suggestion Matthew E. Falagas
There is an increasing trend toward the use of electronic databases of scientifi c information, such as the PubMed database of the National Library of Medicine and the various databases of the Institute for Scientifi c Information (ISI). These databases are frequently used nowadays for various purposes, including the peer-review process of papers submitted for publication in scientifi c journals. Most of the scientifi c journals now use a Web-based peer-review system that offers editors, peer reviewers, and publishers the capability to check the previous papers published by authors submitting a manuscript for consideration for publication [1]. In addition, these databases are frequently searched in an attempt to select potential speakers for scientifi c conferences and to obtain data for possible collaborators for a multicenter study, as well as in the process of evaluating the research productivity of scientists-which is being used for various purposes. However, it is widely known that a considerable proportion of authors share the same last name and fi rst initial. This seems to be the case for people of most ethnic heritages. In addition, authors of scientifi c publications do not frequently use their middle initial, which contributes to the confusion regarding the assignment of publications to the appropriate author. Frequently, it takes considerable effort and time to assign publications to the appropriate authors, particularly if there are authors that share the same last name and fi rst initial (with or without the middle initial). This is usually based on the pattern of research interests, as well as the institutional affi liations of the various authors with the same name. In fact, this task is often impossible.
In order to decrease the problems arising from authors with identical names, I suggest the introduction of a unique author identifi cation number (UAIN) in modern electronic databases of scientifi c information. I further suggest that such an identifi cation number may be hidden in the electronic databases, i.e., it is not necessary for the UAIN to appear when reviewing the record of a publication. This function of the electronic databases could start operating after the providers of the databases are given a reasonable time to prepare. To avoid the resources needed to update the electronic databases with the appropriate assignment of publications to each author, I suggest that the UAIN not be used retrospectively. In this case, the record of publications for a specifi c author would be divided into two parts. The publications that are prospectively connected to a given author with a specifi c UAIN would have an indicator denoting this, while older publications (before the introduction of the UAIN) would not have such an indicator.

Matthew K. Wynia, Vanessa Northington Gamble
David Wendler and colleagues [1] have provided important data to help understand disparities in access to medical research among minorities. It is unfortunate, however, that they draw an unwarranted conclusion from a set of extremely heterogeneous studies. Worse still, by suggesting that the substantial body of research demonstrating how common it is for African Americans to mistrust the health-care system [2][3][4] is wrong, the authors imply that we do not need to come to terms with why this mistrust exists and how it should be addressed by the medical profession.
Wendler et al. note the extreme heterogeneity of the trials included in their study, but they ignore how much this affects the reliability of the meta-analytic techniques they employ. First, the vast majority of the "more than 70,000" patients studied was only involved in survey research-where large differences in response rates between races are not generally seen. Looking only at the clinical trials, the numbers are much smaller and the data become much more diffi cult to summarize. Among the seven surgical intervention trials studied, two have statistically signifi cant differences between minority enrollment and white enrollment. In one, whites had about 2.7 times greater odds of enrollment than minorities, while in the other, minorities had about 1.6 times greater odds of enrollment than whites. In the ten clinical trials studied, three had statistically different enrollment rates; they, too, had greatly diverging results. For the most part, though, the clinical trials that Wendler et al. examined enrolled so few minority patients (in half of the studies, fewer than 50 minority patients were even asked to enroll), and they are so vastly different in design and objectives that very little information can be reliably gleaned from pooling their results. In fact, one of the largest trials included-the Minority-Based Community Clinical Oncology Program (MBCCOP) cancer trial, which included more than 400 African Americans-was specifi cally designed to appeal to minority patients, making any assumptions about its generalizability to all medical research extremely suspect. It is well known that meta-analysis is subject to this sort of problem; statistical tricks simply can't account for fundamental differences in studies.
Despite these scientifi c weaknesses, Wendler et al. are right to conclude that it is inappropriate to focus on changing African Americans' attitudes of mistrust, but not because those attitudes don't exist. Many minorities don't feel welcome and respected within the health-care system. Those who do come in have already crossed a threshold of trust, at least with their individual doctor. Those who don't come in, of course, will never have the opportunity to be asked to enroll in a clinical trial. Instead, the reason it would be inappropriate to focus on changing patient attitudes is because these attitudes of mistrust are based on a history of untrustworthy behavior by the health professions, which must be acknowledged and rectifi ed. In other words, the medical profession should not focus on making minorities be more trusting; we should focus on ensuring that we are becoming trustworthy. illegal immigrants (about 10.86% of 4.6 million ethnic minorities) [4,5].
In this regard, the apprehension of being traced as illegal immigrants poses a defi nite barrier to participating in any research activity. It is indeed a sensitive issue. Similar to the doctor-patient relationship, a confi dential channel should be ensured between the researcher and the participant. It is the duty of the researcher to explain during the time of consent that this research has nothing to do with participants' citizenship status, and no information will be used in any way against them. Legislation must be passed to provide legal immunity to all participants regardless of their legal status. I believe adopting such methodology will increase the number of participants belonging to ethnic minorities. Moreover, research would be carried out on a truly representative structure of the local population.